Matthias Pinter
Impact in
- Hepatology top 0.1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
- Liver physiology and pathology
- Hepatitis C virus research
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
Papers in
- Hepatology 183
- Hepatocellular Carcinoma Treatment and Prognosis 137
- Liver Disease and Transplantation 43
- Hepatitis C virus research 5
- Oncology 36
- Cancer Immunotherapy and Biomarkers 23
- Inflammatory Biomarkers in Disease Prognosis 6
- Co-authors
- Markus Peck‐Radosavljevic (42 shared papers)Michael Trauner (86 shared papers)Wolfgang Sieghart (32 shared papers)Bernhard Scheiner (76 shared papers)Thomas Reiberger (69 shared papers)Rakesh K. Jain (3 shared papers)Christian Müller (13 shared papers)Florian Hucke (17 shared papers)
In The Last Decade
Matthias Pinter
207 papers receiving 9.3k citations
Matthias Pinter's Hit Papers
Peers
Comparison fields: 5 of 105
- Hepatology 6k
- Oncology 1.8k
- Cancer Research 382
- Epidemiology 781
- Immunology 314
Countries citing papers authored by Matthias Pinter
This map shows the geographic impact of Matthias Pinter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias Pinter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias Pinter more than expected).
Fields of papers citing papers by Matthias Pinter
This network shows the impact of papers produced by Matthias Pinter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias Pinter. The network helps show where Matthias Pinter may publish in the future.
Co-authors
The 25 scholars most cited alongside Matthias Pinter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 230 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | NASH limits anti-tumour surveillance in immunotherapy-treated HCC Hit paper breakdown → | 2021 | 1029 |
| 2 | Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2023 | 374 |
| 3 | 2016 | 372 | |
| 4 | 2013 | 283 | |
| 5 | The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma Hit paper breakdown → | 2020 | 269 |
| 6 | 2017 | 267 | |
| 7 | 2012 | 257 | |
| 8 | Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score Hit paper breakdown → | 2021 | 230 |
| 9 | 2016 | 221 | |
| 10 | Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study Hit paper breakdown → | 2022 | 191 |
| 11 | 2020 | 189 | |
| 12 | 2012 | 180 | |
| 13 | 2018 | 180 | |
| 14 | Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial Hit paper breakdown → | 2025 | 161 |
| 15 | 2020 | 157 | |
| 16 | 2009 | 151 | |
| 17 | 2014 | 140 | |
| 18 | 2018 | 136 | |
| 19 | 2018 | 134 | |
| 20 | 2019 | 133 |
About Matthias Pinter
Matthias Pinter is a scholar working on Hepatology, Oncology, Epidemiology, Cardiology and Cardiovascular Medicine and Pathology and Forensic Medicine, having authored 230 papers that have together received 9.4k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (137 papers), Liver Disease and Transplantation (43 papers), Cancer Immunotherapy and Biomarkers (23 papers), Liver Disease Diagnosis and Treatment (16 papers), Inflammatory Biomarkers in Disease Prognosis (6 papers), Hepatitis C virus research (5 papers), Viral Infections and Immunology Research (5 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers). The work is most often cited by research in Hepatology (6k citations), Oncology (1.8k citations), Cancer Research (382 citations), Epidemiology (781 citations) and Immunology (314 citations). Matthias Pinter has collaborated with scholars based in Austria, Germany and Italy. Frequent co-authors include Markus Peck‐Radosavljevic, Michael Trauner, Wolfgang Sieghart, Bernhard Scheiner, Thomas Reiberger, Rakesh K. Jain, Christian Müller, Florian Hucke, Ivo W. Graziadei and Wolfgang Vogel. Their work appears in journals such as Journal of Hepatology, JHEP Reports, Alimentary Pharmacology & Therapeutics, Digestive and Liver Disease and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.